2013
Safety profile of recombinant poxviral TRICOM vaccines.
Kim J, Marte J, Singh N, Heery C, Madan R, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Kantoff P, Gulley J. Safety profile of recombinant poxviral TRICOM vaccines. Journal Of Clinical Oncology 2013, 31: e16036-e16036. DOI: 10.1200/jco.2013.31.15_suppl.e16036.Peer-Reviewed Original ResearchThrombotic thrombocytopenic purpuraAdverse eventsPoxviral vaccinesSafety profileMetastatic castration-resistant prostate cancerRandomized phase II trialCastration-resistant prostate cancerEmergent adverse eventsMedian overall survivalPhase II trialPhase III trialsTherapeutic cancer vaccinesResistant prostate cancerFavorable safety profileGranulocyte-macrophage colony-stimulating factorProstate-specific antigenRoute of administrationColony-stimulating factorII trialIII trialsOverall survivalVaccine injectionImmune adjuvantsThrombocytopenic purpuraCancer vaccines
2012
Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers 2012, 4: 1229-1246. PMID: 24213505, PMCID: PMC3712729, DOI: 10.3390/cancers4041229.Peer-Reviewed Original ResearchClinical benefitIntermediate markersImmunotherapy clinical trialsTherapeutic cancer vaccinesPotential clinical roleTumor growth kineticsOverall survivalImmune infiltratesClinical outcomesCytokine responsesCancer vaccinesCellular immunityIntermediate biomarkersPeripheral bloodCancer immunotherapyClinical trialsParadoxical patternProstate cancerClinical roleProspective assessmentSystemic responseTherapy mechanismsBiomarkersImmunotherapySurvivalPoxviral vectors for cancer immunotherapy
Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opinion On Biological Therapy 2012, 12: 463-478. PMID: 22413824, PMCID: PMC3482162, DOI: 10.1517/14712598.2012.668516.Peer-Reviewed Original ResearchConceptsAppropriate patient selectionClinical trial designPatient selectionTrial designMetastatic castration-resistant prostate cancerPlacebo-controlled clinical trialCastration-resistant prostate cancerNovel immunologic approachesPhase III randomizedScience of immunotherapyImmune-based therapiesMultiple costimulatory moleculesTumor-associated antigensEarly clinical studiesAppropriate end pointsPoxviral vaccinesPSA-TRICOMHormonal therapyNovel immunotherapiesPoxviral vectorsCancer vaccinesCostimulatory moleculesCancer immunotherapyTreatment modalitiesImmunologic approaches
2011
Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine
Kim JW, Madan RA, Gulley JL. Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine. Clinical Genitourinary Cancer 2011, 10: 43-46. PMID: 22019260, PMCID: PMC3279569, DOI: 10.1016/j.clgc.2011.09.003.Peer-Reviewed Original Research